BRCA1 and neoplasm: Besides, by comparing the presentation of dominant parameters among specific mutations subgroups, BRCA1‐mutated tumours were found with higher levels of potent immunotherapy‐responsive signatures, providing a rational for the ICIs treatment for BRCA1‐mutation carriers with HGSOCs.